Recon

MicroPort Orthopedics Announces Launch of HA Coated Collared Hip Stem and Cemented Collared Hip Stem, Expanding its Hip Stem Portfolio

This expansion of the Profemur® Gladiator® Hip Stem System for Total Hip Arthroplasty provides surgical flexibility to more effectively treat patients

Arlington, Tenn., Feb. 18, 2021MicroPort Orthopedics, an international leader in orthopedic devices and technologies, today announced the availability of its Profemur® Gladiator® HA Collared Stem and Profemur® Gladiator® Cemented Collared Stem. Combined with its current Profemur® Gladiator® Plasma Stem, the Gladiator® Hip Stem System is now complete, offering  a wide range of indications in the treatment of both high demand total hip arthroplasties and low demand fracture patients.  

Designed for primary hip replacement surgery, the Profemur® Gladiator® Hip Stems all offer a triple wedge tapered design with distinct geometry. The hip stem is designed with a reduced lateral shoulder convenient for tissue-sparing techniques, making it perfectly suited to be used with MicroPort’s disruptive innovation through the Anterior Path® surgical approach.  The Profemur® line of Hip Stems gives surgeons the versatility to address their patients’ needs with one set of instruments in this truly comprehensive system.

“By allowing surgeons to cater a femoral hip system to their preferred techniques, we have created a customizable hip system that is Simply Versatile™ in its ability to exceed the needs of each surgeon, designed to help our surgeons more effectively treat patients,” said Benny Hagag, President of MicroPort Orthopedics. “This customization to tissue-sparing techniques allows for streamlined preoperative planning, excellent patient outcomes1,2, and a quicker recovery3. The proof is in our patients.” 

MicroPort Orthopedics offers various products and techniques to help patients receiving total hip and knee replacements achieve Full Function, Faster4,5. For more information on the Profemur® Gladiator® Hip System and MicroPort Orthopedics, visit www.microportortho.com.

###

*Individual results and activity levels after surgery vary and depend on many factors including age, weight and prior activity level. There are risks and recovery times associated with surgery and there are certain individuals who should not undergo surgery. Not all products and options are available in all countries.

Routing Number: 023564

About MicroPort Orthopedics

MicroPort Orthopedics leverages extensive experience in orthopedics and excellent clinical results to improve patient outcomes and drive provider satisfaction across the globe. The mission of MicroPort Orthopedics is to become the trusted partner of healthcare professionals who share a belief that hip and knee replacements of the past are not good enough for the patient today. In partnership with surgeons, MicroPort helps patients get back on their feet quickly. With a focus on innovation combined with demonstrated capability to deliver the resources of an industry leader, MicroPort Orthopedics is helping patients worldwide achieve full function faster each and every day. To learn more, visit www.microportortho.com.

PR Contact

Erika Beerbower

AM Public Relations

ebeerbower@ampublicrelations.com

References

1. Australian Orthopaedic Association National Joint Replacement Registry (AO-ANJRR), Automated Indus-try Report System (AIRS), ID

No. 3178 for MicroPort Or-thopedics, Profemur Gladiator Total Conventional Hip, (Procedures from 27 July 2012 – 26 August 2020),

Accessed 13 October 2020, AOA, Adelaide: 1-19.

2. MPO Data on file.

3. As compared to traditional surgery. Gofton W, Chow J, Olsen KD, Fitch DA. Thirty-day readmission rate and discharge status following total hip arthroplasty using the SuperPath surgical technique. Int Orthop. 2015;39:847-51  

4. QurashiS, ChinnappaJ, Lord SJ, NazhaA, Gordon J, Chow J. DrivingafterMicro-Invasive Total Hip Arthroplasty. Journal of Arthroplasty 2017 May;32(5)

5. MPO Data on file.

Print Friendly, PDF & Email
Tags

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button
Close